New mRNA shot targets tumors in Last-Resort cancer patients
NCT ID NCT07562815
First seen May 02, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This early-phase study tests a new mRNA treatment (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors to help the body fight cancer. The main goal is to check safety, and researchers will also look for signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital
Chengdu, Sichuan, 610000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.